Roche and Ex­elix­is de­tail rare suc­cess for Cabome­tyx-Tecen­triq com­bo in prostate can­cer

The com­bi­na­tion of Roche’s check­point in­hibitor Tecen­triq and Ex­elix­is’ ki­nase in­hibitor Cabome­tyx staved off dis­ease pro­gres­sion of ad­vanced prostate can­cer for longer than a sec­ond …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER